← All trials
NCT04195633
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2020
- Primary completion
- Dec 27, 2022
- Completion date
- Dec 27, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- MedacCollaborator
Drugs studied
Indications studied
- Burkitt Lymphoma
- Hodgkin Disease
- Leukemia
- Lymphoma
- Lymphoma, Follicular
- Myelodysplastic Syndromes
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Prolymphocytic
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.